MOTS-c: Mitochondrial-Derived Peptide for Metabolism and Longevity

MOTS-c is one of the most remarkable discoveries in longevity science of the past decade. Encoded not by the nuclear genome but by mitochondrial DNA, this 16-amino-acid peptide acts as a systemic metabolic regulator — responding to cellular stress, improving insulin sensitivity, and extending lifespan in animal models. It represents a fundamentally new class of signaling molecules.

The Mitochondrial Origin of MOTS-c

For decades, mitochondria were thought to encode only 13 proteins, all components of the oxidative phosphorylation machinery. In 2015, researchers at the University of Southern California discovered that mitochondrial DNA also encodes small open reading frames that produce bioactive peptides. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) was the first of these mitochondria-derived peptides (MDPs) to be characterized in detail.

MOTS-c is released from mitochondria in response to metabolic stress and travels to the nucleus, where it regulates genes involved in glucose and lipid metabolism. This nucleus-mitochondria communication loop positions MOTS-c as a master metabolic regulator.

Metabolic Effects and Insulin Sensitization

The most well-documented effect of MOTS-c is improved insulin sensitivity. In obese, diabetic mice, MOTS-c injection reversed insulin resistance, reduced fat accumulation, and normalized blood glucose — without changes in food intake. The mechanism involves activation of AMPK (AMP-activated protein kinase), the master energy sensor, and suppression of the folate cycle, which regulates de novo purine synthesis and cellular energetics.

Human data are emerging. Circulating MOTS-c levels decline with age and are lower in obese individuals. Studies in Korean populations found that MOTS-c genetic variants are associated with longevity, supporting its role in aging biology.

Exercise Mimicry and Physical Performance

A landmark 2021 study published in Nature Communications showed that MOTS-c levels rise dramatically with exercise, suggesting it partially mediates the metabolic benefits of physical activity. When sedentary aged mice were given MOTS-c injections, they showed improved exercise capacity and muscle metabolism — essentially mimicking some of the systemic effects of exercise training.

This makes MOTS-c particularly interesting for aging populations who cannot exercise at sufficient intensity to drive metabolic adaptations.

Longevity Research

In C. elegans, overexpression of MOTS-c homologs extends lifespan. In mice, MOTS-c treatment extends median lifespan when initiated in middle age. The longevity effects appear tied to improved mitochondrial function, reduced inflammation, and preserved metabolic homeostasis rather than any single pathway.

MOTS-c levels in humans peak in young adulthood and decline progressively with age. Restoring youthful MOTS-c signaling is a central hypothesis driving its therapeutic development.

Dosing and Administration

Research protocols in rodents use subcutaneous doses of 0.5-5 mg/kg. Human-equivalent doses have not been established in clinical trials. Researchers exploring MOTS-c outside formal trials typically use 5-10 mg subcutaneously 2-3 times per week, though this is extrapolated from animal studies.

MOTS-c is not orally bioavailable due to peptide degradation in the GI tract. Subcutaneous injection is the standard administration route. Half-life is short — estimated at under 4 hours — necessitating frequent dosing.

Regulatory and Access Status

MOTS-c is not FDA-approved and is classified as a research peptide. It is available from peptide suppliers in the research market, though quality varies significantly between vendors. No large-scale human clinical trials have been published as of early 2026.

FAQ

Does MOTS-c replace exercise? No. While MOTS-c mimics some metabolic effects of exercise, it does not replicate the cardiovascular, structural, and neurological benefits of physical training. It may be an adjunct for those with limited exercise capacity.

How does MOTS-c relate to aging? MOTS-c declines with age in humans, and low levels correlate with metabolic dysfunction. Restoring MOTS-c signaling may slow metabolic aging, though long-term human studies are lacking.

Is MOTS-c safe? Animal studies show a favorable safety profile. Human safety data are limited to small studies. Given its endogenous nature, significant toxicity is not expected, but formal safety characterization is incomplete.

Related Articles

• Humanin: Mitochondrial Peptide Against Alzheimer's and Aging
• Peptide Stack for Longevity: Epithalon, SS-31, Thymalin, and MOTS-c
• Peptides for Energy: MOTS-c, Mitochondrial Peptides, and GH Axis
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss

Track your supplements in Optimize.